Please login to the form below

Not currently logged in
Email:
Password:

cancer immunotherapies

This page shows the latest cancer immunotherapies news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘post-Brexit’ R&D alliance

One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... in liver cancer and see if immunotherapies can be a treatment option.

Latest news

  • London cancer hub launched by Cancer Research UK London cancer hub launched by Cancer Research UK

    London cancer hub launched by Cancer Research UK. Specialist centres unite to collaborate on immunotherapies such as CAR-T. ... Francis Crick Institute – bringing together researchers who will collaborate on cancer biotherapeutics including

  • Affimed rockets on $5bn-plus Roche immuno-oncology deal Affimed rockets on $5bn-plus Roche immuno-oncology deal

    Affimed rockets on $5bn-plus Roche immuno-oncology deal. Swiss pharma giant set to pay $96m upfront to discover new cancer immunotherapies. ... German biotech Affimed saw its share price more than triple yesterday after Roche’s Genentech agreed an

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    including a go-ahead last year in BRAF V600-postitive non-small cell lung cancer (NSCLC). ... talk of using the cancer immunotherapies and small-molecule BRAF/MEK pair in combination.

  • China’s BeiGene takes PD-1 antibody into pivotal trials China’s BeiGene takes PD-1 antibody into pivotal trials

    The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure. ... There is a huge pent-up need for new cancer immunotherapies.

  • Daily brief: Novartis spends big on ezcema, Daily brief: Novartis spends big on ezcema,

    Kite has signed a deal with Netherlands-based Gadeta, a privately-held company focused on developing of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs). ... targets in cancer cells, according to preclinical models evaluating the

More from news
Approximately 24 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the failure of two immunotherapies in the MYSTIC lung cancer trial last year – but the company ... The park is also home to the Cancer Research UK Institute, a

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... Precision cancer treatment. The shift towards immunotherapies has been accompanied by another key trend – targeting

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell ... Tucatinib is currently being evaluated in a phase

  • Deal Watch November 2015 Deal Watch November 2015

    A package deal covering up to five cancer immunotherapies, the headline value was $1.56bn with an upfront fee of $60m; the subsequent milestone terms per product could reach in excess ... Sanofi will gain access to BioNTech's mRNA formulation technology

  • Pharma deals in June 2015 Pharma deals in June 2015

    Immune modulators in cancer and beyond. Both Juno Therapeutics and Celgene have had a busy month in forming alliances in the immunotherapy area. ... Near the close of the month, Juno and Celgene announced a $1bn, 10-year collaboration to develop novel

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    Gaweco will lead Apeiron’s immuno-oncology programmes, overseeing the discovery, clinical and medical functions of the company’s new molecular entities pipeline of cancer immunotherapies. ... His outreach into the worldwide pharmaceutical markets

  • Targovax strengthens board of directors Targovax strengthens board of directors

    of our novel and complementary portfolio of cancer immunotherapies.”.

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral

  • Merck’s Richard Murray joins Jounce as CEO Merck’s Richard Murray joins Jounce as CEO

    Merck’ s Richard Murray joins Jounce as CEO. He brings experience in cancer immunotherapies to the US biotech. ... pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    These sales made Novartis the third largest pharma company in cancer for the year. ... The area of anti-PD1 cancer immunotherapies looks to be an important one for many companies, with Bristol-Myers Squibb, Roche and AstraZeneca all developing their own

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics